POMALYST (pomalidomide) capsules, for oral use. Initial US Approval: 2013

POMALYST (pomalidomide) capsules, for oral use. Initial US Approval: 2013

INDICATIONS AND USAGE
POMALYST is a thalidomide analogue indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.
DOSAGE FORMS & STRENGTHS
Capsules: 1 mg, 2 mg, 3 mg and 4 mg
Manufactured By: Celgene Corporation
Prescribing Information URL: Click Here

Access to POMALYST ® (pomalidomide) capsules: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Pomalidomide (INN; marketed as Pomalyst in the US and Imnovid in the European Union and Russia) is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator.[medical citation needed].
Pomalidomide was approved in February 2013, by the US Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma. It has been approved for use in people who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. It received a similar approval from the European Commission in August 2013.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.